DiaMedica Therapeutics (NASDAQ:DMAC – Get Free Report) is expected to announce its earnings results before the market opens on Monday, March 17th. Analysts expect the company to announce earnings of ($0.17) per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.
DiaMedica Therapeutics Price Performance
DMAC opened at $5.77 on Friday. The company has a fifty day moving average price of $5.95 and a 200-day moving average price of $5.05. The firm has a market capitalization of $246.73 million, a P/E ratio of -10.30 and a beta of 1.52. DiaMedica Therapeutics has a one year low of $2.14 and a one year high of $6.82.
Analyst Upgrades and Downgrades
Separately, HC Wainwright restated a “buy” rating and set a $7.00 price target on shares of DiaMedica Therapeutics in a research report on Friday, November 15th.
About DiaMedica Therapeutics
DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.
Featured Stories
- Five stocks we like better than DiaMedica Therapeutics
- How Can Investors Benefit From After-Hours Trading
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- The How and Why of Investing in Gold Stocks
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- Pros And Cons Of Monthly Dividend Stocks
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
